Radiosensitization of cetuximab on human tongue cancer cell line Tca8113
- Author:
- No author available
- Journal Title:
- Chinese Journal of Radiological Medicine and Protection
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.0254-5098.2012.04.005
- Key Word:
- 西妥昔单抗;Tca8113细胞;放射增敏;细胞周期;凋亡;Cetuximab;Tca8113;Radiosensitization;Cell cycle;Apoptosis
Abstract： Objective To investigate the mechanism of radiosensitization by cetuximab (C225) on human tongue cancer Tca8113 cell line in vitro.Methods Tca8113 cell line with and without C225 treatment received 6 MV X-ray irradiation of different doses (0, 2,4,6, 8 and 10 Gy). Cell proliferation,cell-cycle distribution and clonogenic survival were analyzed through cell counting,MTT,colony formation assay,and flow cytometry,respectively.Results After irradiation of different doses,the growth inhibition rates in C225 group were higher than control (t =- 15.6 - -3.0,P＜0.05),the radiobiological parameters (D0,Dq,N,and SF2 ) in C225 group were lower than control so that SER of C225 group was 1.353,and the proportions of G0/G1 cells in C225 group were higher than control ( t =-7.64,-7.89,-4.78,P ＜0.05 ) at 4,6,8 Gy.When the irradiation doses increased,the early phase apoptosis in both groups increased at first and then decreased with the maximum difference at 4 Gy [(7.96±0.36)％ in C225 group and (4.13 ±0.29)％ in control group,t =-12.75,P＜0.01 ].Conclusions C225 has radiosensitization effect on Tca8113 cell line,possible through Go/G1 arrest and induction of apoptosia.
- [1]Fischel JL,Tiffon C,Dubreuil A,etc.Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.[J].2003,89(3).
- [2]Arteaga CL.Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.[J].2002,29(5 Suppl.14).
- [3]Liccardi G,Hochhauser D,Hartley JA.EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.[J].2011,71(3).
- [4]Bilodeau M,Ethier C,Musallam L,etc.EGF mediates protection against Fas-induced apoptosis by depleting and oxidizing intracellular GSH stocks.[J].2004,198(1).
- [5]Blick SK,Scott LJ.Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.[J].2007,67(17).
- [6]Norberg-Spaak L,Farnebo L,Roberg K,etc.Number of negative points: a novel method for predicting radiosensitivity in head and neck tumor cell lines.[J].2008,20(2).
- [7]Dicke K,Herbst RS,Hong WK,etc.Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.[J].2005,23(24).
- [8]Ohashi M,Kondo G,Iwase M,etc.Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor.[J].2006,42(7).
- [9]Peltola K,Hollmen M,Maula SM,etc.Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.[J].2009,11(7).
- [10]Kraus DH,Wolden SL,Lake S,etc.Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.[J].2006,24(7).